BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36925722)

  • 1. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies.
    Guo H; Jiang J; Shen S; Ge X; Fan Q; Zhou B; Cheng L; Ju B; Zhang Z
    iScience; 2023 Apr; 26(4):106283. PubMed ID: 36925722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
    Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
    Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
    Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menachery V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    Cell Rep; 2022 May; 39(7):110812. PubMed ID: 35568025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron.
    Patel A; Kumar S; Lai L; Keen M; Valanparambil R; Chakravarthy C; Laughlin Z; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Davis CW; Wrammert J; Sharma A; Ahmed R; Suthar MS; Murali-Krishna K; Chandele A; Ortlund E
    Cell Rep; 2023 Sep; 42(9):113150. PubMed ID: 37708028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
    Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
    Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.
    Lu RM; Liang KH; Chiang HL; Hsu FF; Lin HT; Chen WY; Ke FY; Kumari M; Chou YC; Tao MH; Yi-Ling Lin ; Wu HC
    Heliyon; 2023 May; 9(5):e15587. PubMed ID: 37090428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization.
    Pastorio C; Noettger S; Nchioua R; Zech F; Sparrer KMJ; Kirchhoff F
    iScience; 2023 Nov; 26(11):108299. PubMed ID: 38026181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
    Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants.
    Alcantara MC; Higuchi Y; Kirita Y; Matoba S; Hoshino A
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
    Chen Z; Li J; Zheng J; Jin Y; Zhang Y; Tang F; Li J; Cheng H; Jiang L; Wen H; Hong C; Zeng X; Huang S; Lu B; Li L; Wang Z
    J Med Virol; 2023 Feb; 95(2):e28539. PubMed ID: 36719034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.